Slow-release mexiletine in the treatment of ventricular premature beats. Comparison with long-acting dihydroquinidine

D. Accettura, L. De Toma, S. G. Mangini, R. Lagioia, D. Scrutinio, F. Mastropasqua, C. Caiati, P. Rizzon

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This double-blind, placebo-controlled, cross-over study was designed to compare the efficacy of orally administered slow-release mexiletine (SM) (360 mg 2 bid for 5 days) and long-acting dihydroquinidine (LD) (250 mg 2 bid for 5 days) in reducing ventricular premature beats (VPBs). The protocol was completed by 12 hospitalized patients. Entry was determined by the presence of more than 720 VPBs in 2 pre-trial 24 hours Holter monitorings. The study protocol was as follows: during the 1st, 3rd and 5th three-day periods, each patient received the placebo of both drugs on single blind condition; during the 2nd and 4th five-day periods, the patients were given on double blind condition SM or LD (double dummy technique) and placebo of the other drug according to a cross-over design. The 5 periods were consecutive; at the end of each period the patients underwent a 24 hours Holter monitoring. The absence of significant VPBs/hour changes during the run-in period and the 3 placebo periods (522 ± 168, 461 ± 182, 547 ± 180 respectively) confirmed the stability of the arrhythmia during the whole study. Compared to placebo, SM and LD reduced VPBs/hour to 353 ± 194 (p 70% was observed in 67% and 33% of cases with SM and LD, respectively. SM and LD also induced a reduction of couplets/24 hours from 127 ± 59 to 21 ± 11 (p

Original languageEnglish
Pages (from-to)999-1003
Number of pages5
JournalCardiologia
Volume32
Issue number9
Publication statusPublished - 1987

Fingerprint

Mexiletine
Ventricular Premature Complexes
Placebos
Ambulatory Electrocardiography
Cross-Over Studies
Therapeutics
Pharmaceutical Preparations
Cardiac Arrhythmias
hydroquinidine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Slow-release mexiletine in the treatment of ventricular premature beats. Comparison with long-acting dihydroquinidine. / Accettura, D.; De Toma, L.; Mangini, S. G.; Lagioia, R.; Scrutinio, D.; Mastropasqua, F.; Caiati, C.; Rizzon, P.

In: Cardiologia, Vol. 32, No. 9, 1987, p. 999-1003.

Research output: Contribution to journalArticle

@article{9d3f5e64bc8046b889db388b6236668c,
title = "Slow-release mexiletine in the treatment of ventricular premature beats. Comparison with long-acting dihydroquinidine",
abstract = "This double-blind, placebo-controlled, cross-over study was designed to compare the efficacy of orally administered slow-release mexiletine (SM) (360 mg 2 bid for 5 days) and long-acting dihydroquinidine (LD) (250 mg 2 bid for 5 days) in reducing ventricular premature beats (VPBs). The protocol was completed by 12 hospitalized patients. Entry was determined by the presence of more than 720 VPBs in 2 pre-trial 24 hours Holter monitorings. The study protocol was as follows: during the 1st, 3rd and 5th three-day periods, each patient received the placebo of both drugs on single blind condition; during the 2nd and 4th five-day periods, the patients were given on double blind condition SM or LD (double dummy technique) and placebo of the other drug according to a cross-over design. The 5 periods were consecutive; at the end of each period the patients underwent a 24 hours Holter monitoring. The absence of significant VPBs/hour changes during the run-in period and the 3 placebo periods (522 ± 168, 461 ± 182, 547 ± 180 respectively) confirmed the stability of the arrhythmia during the whole study. Compared to placebo, SM and LD reduced VPBs/hour to 353 ± 194 (p 70{\%} was observed in 67{\%} and 33{\%} of cases with SM and LD, respectively. SM and LD also induced a reduction of couplets/24 hours from 127 ± 59 to 21 ± 11 (p",
author = "D. Accettura and {De Toma}, L. and Mangini, {S. G.} and R. Lagioia and D. Scrutinio and F. Mastropasqua and C. Caiati and P. Rizzon",
year = "1987",
language = "English",
volume = "32",
pages = "999--1003",
journal = "Cardiologia (Rome, Italy)",
issn = "0393-1978",
publisher = "Societa Italiana di Cardiologia",
number = "9",

}

TY - JOUR

T1 - Slow-release mexiletine in the treatment of ventricular premature beats. Comparison with long-acting dihydroquinidine

AU - Accettura, D.

AU - De Toma, L.

AU - Mangini, S. G.

AU - Lagioia, R.

AU - Scrutinio, D.

AU - Mastropasqua, F.

AU - Caiati, C.

AU - Rizzon, P.

PY - 1987

Y1 - 1987

N2 - This double-blind, placebo-controlled, cross-over study was designed to compare the efficacy of orally administered slow-release mexiletine (SM) (360 mg 2 bid for 5 days) and long-acting dihydroquinidine (LD) (250 mg 2 bid for 5 days) in reducing ventricular premature beats (VPBs). The protocol was completed by 12 hospitalized patients. Entry was determined by the presence of more than 720 VPBs in 2 pre-trial 24 hours Holter monitorings. The study protocol was as follows: during the 1st, 3rd and 5th three-day periods, each patient received the placebo of both drugs on single blind condition; during the 2nd and 4th five-day periods, the patients were given on double blind condition SM or LD (double dummy technique) and placebo of the other drug according to a cross-over design. The 5 periods were consecutive; at the end of each period the patients underwent a 24 hours Holter monitoring. The absence of significant VPBs/hour changes during the run-in period and the 3 placebo periods (522 ± 168, 461 ± 182, 547 ± 180 respectively) confirmed the stability of the arrhythmia during the whole study. Compared to placebo, SM and LD reduced VPBs/hour to 353 ± 194 (p 70% was observed in 67% and 33% of cases with SM and LD, respectively. SM and LD also induced a reduction of couplets/24 hours from 127 ± 59 to 21 ± 11 (p

AB - This double-blind, placebo-controlled, cross-over study was designed to compare the efficacy of orally administered slow-release mexiletine (SM) (360 mg 2 bid for 5 days) and long-acting dihydroquinidine (LD) (250 mg 2 bid for 5 days) in reducing ventricular premature beats (VPBs). The protocol was completed by 12 hospitalized patients. Entry was determined by the presence of more than 720 VPBs in 2 pre-trial 24 hours Holter monitorings. The study protocol was as follows: during the 1st, 3rd and 5th three-day periods, each patient received the placebo of both drugs on single blind condition; during the 2nd and 4th five-day periods, the patients were given on double blind condition SM or LD (double dummy technique) and placebo of the other drug according to a cross-over design. The 5 periods were consecutive; at the end of each period the patients underwent a 24 hours Holter monitoring. The absence of significant VPBs/hour changes during the run-in period and the 3 placebo periods (522 ± 168, 461 ± 182, 547 ± 180 respectively) confirmed the stability of the arrhythmia during the whole study. Compared to placebo, SM and LD reduced VPBs/hour to 353 ± 194 (p 70% was observed in 67% and 33% of cases with SM and LD, respectively. SM and LD also induced a reduction of couplets/24 hours from 127 ± 59 to 21 ± 11 (p

UR - http://www.scopus.com/inward/record.url?scp=0023413932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023413932&partnerID=8YFLogxK

M3 - Article

C2 - 2446764

AN - SCOPUS:0023413932

VL - 32

SP - 999

EP - 1003

JO - Cardiologia (Rome, Italy)

JF - Cardiologia (Rome, Italy)

SN - 0393-1978

IS - 9

ER -